Articles tagged with Drug Resistance
Researchers have discovered biomarkers that predict response to treatment and proposed therapeutic solutions for patients who do not respond well. The study identifies the molecular mechanisms determining patients' response to certain drugs used in clinical trials.
Breast cancer cells that develop resistance to tamoxifen therapy increase production of metadherin, a protein associated with recurrence. Reintroducing microRNA 375 restores sensitivity to the drug, suggesting its role in malignancy and resistance development.
Researchers at Moffitt Cancer Center have found a new way to overcome resistance to drugs that target the BRAF gene mutation in melanoma. The study, led by Jeffrey S. Weber and Keiran S. Smalley, showed that an inhibitor called XL888 can restore effectiveness in patients who have developed resistance to existing treatments.
Researchers at RIKEN Brain Science Institute discovered a yeast prion called Mod5 that confers survival advantages by granting cellular resistance to antifungal agents. The study reveals the active role of prion conversion in cellular fitness adaptation, providing new insights into the broader function of prions in living organisms.
Researchers use groundbreaking gene sequencing technology to rapidly detect FLT3 mutations in AML patients who have relapsed on therapy. This discovery may help develop new therapies to treat AML, a type of leukemia characterized by rapid white blood cell growth.
A team from UNC Health Care has developed a broad-based test to measure the activation of protein kinases, enabling the measurement of drug resistance in cancer. The test can identify combinations of drugs that block resistance, offering personalized therapies for breast cancer.
A new study reveals that artemisinin-resistant malaria has emerged and increased rapidly along the Thailand-Myanmar border, with parasite clearance half-lives lengthening from 2.6 hours in 2001 to 3.7 hours in 2010. The proportion of slow-clearing infections increased from 0.6% in 2001 to 20% in 2010.
A recent study published in the Lancet found a critical point in global efforts to control and eliminate malaria due to artemisinin resistance in western Thailand. Researchers identified a major region of the malaria parasite genome associated with artemisinin resistance, raising hope for effective molecular markers to monitor its spread.
A genetics study identifies key genome region underlying artemisinin resistance in malaria parasite, increasing concern about its spread to India and Africa. The region may provide a tool for mapping resistance, but containing its spread is expected to be challenging.
Scientists at Washington University School of Medicine have devised a treatment that prevents optic nerve injury in glaucoma by exposing mice to low levels of oxygen. The study found that preconditioning induced tolerance protects against neurodegenerative disease, with mice losing only 3% of retinal ganglion cell bodies after 10 weeks.
Researchers propose that non-genetic resistance can occur before genetic mutations, changing the approach to designing combination therapies. This new perspective aims to improve outcomes by understanding how cancers evolve and adapt to extreme challenges.
A study by researchers at the University of Montreal identified cellular and molecular mechanisms that enable opioid pain drug tolerance. They found that receptor recycling plays a key role in tolerance development, suggesting potential strategies for designing longer-acting analgesics.
Researchers at Yale University have created a compound that prevents the growth of the malaria parasite within red blood cells. The compound, developed by Sidney Altman and his team, shows promise in combating drug-resistant strains of the disease, which kills over 1 million people annually.
A study by UCLA's Jonsson Comprehensive Cancer Center found that patients with both MEK1 and BRAF mutations respond equally well to BRAF inhibitor drugs, challenging conventional wisdom. The presence of both mutations does not contribute to drug resistance in melanoma patients.
Researchers at Sanford-Burnham Medical Research Institute found that MLN4924-resistant cancer cells escape death due to a simple mutation in the NEDD8-activating enzyme. The team developed a method to predict how cancer patients will respond to this drug, providing a new path toward personalized medicine.
A study found that a genetic variation in the BIM gene variant occurs in about 15% of the typical East Asian population and contributes to some patients' failure to benefit from tyrosine kinase inhibitor drugs. The researchers identified a novel class of BH3-mimetics as a potential treatment option to overcome this resistance.
A new study by researchers at H. Lee Moffitt Cancer Center has found that the XL888 inhibitor can prevent resistance to chemotherapy drug vemurafenib in melanoma patients, leading to induced apoptosis response and tumor regression. The study suggests a novel approach to managing drug resistance using broadly targeted strategies.
Researchers recommend a stop-and-go approach to balance oxaliplatin dose with neurological side effects, maximizing effectiveness while minimizing harm. Supplements such as calcium and magnesium may mitigate drug damage, improving patient outcomes.
Researchers have mapped the molecular structure of restriction enzymes found in many bacteria, shedding light on how they control bacterial resistance to antibiotics. This knowledge could aid in developing new treatments for superbugs like MRSA, which become resistant to most drugs through genetic exchange.
Researchers have identified key genes responsible for drug resistance in African trypanosomes, leading to a better understanding of how effective treatments work. This knowledge could lead to the development of new diagnostics and therapies to tackle the disease.
Despite significant progress in treating chronic myeloid leukemia, a cure remains elusive for all patients. Research and adherence to treatments are crucial to advancing the field.
Researchers found that MET gene overexpression leads to deregulation of microRNAs, causing gefitinib resistance in lung cancer. Combining targeted drugs with microRNA blockers may improve treatment efficacy.
A recent study warns that counterfeit and substandard anti-malarial medicines are circulating in Africa, posing a significant threat to public health. The medicines may contain wrong active pharmaceutical ingredients or artemisinin derivatives at low levels, leading to drug resistance and increased mortality.
A recent study published in Journal of Oncology reveals that MAL3-101, a heat shock protein 70 inhibitor, exhibits potent anti-myeloma effects both in vitro and in vivo. The compound boosts the effectiveness of proteasome inhibitors like bortezomib when used synergistically.
A University of Texas at Austin chemist has received a $1.6 million grant to develop a simple, paper-based test for detecting drug-resistant tuberculosis. The goal is to create a real-time test that can be used in resource-poor communities without refrigeration.
A comprehensive DNA study of mast cell leukemia identifies two previously unknown mutations that could improve diagnostic power and targeted therapy. The study's findings suggest a diagnostic improvement and an alternative treatment strategy for MCL, with potential implications for other cancers.
A team of researchers identified APNG as a contributor to GBM resistance to temozolomide, with high nuclear expression correlating to poorer survival. Monitoring APNG levels may provide insight into patient response to temozolomide treatment.
Researchers at Loyola University Medical Center report positive results from a clinical trial of an experimental drug targeting tumor stem cells. The study found that the drug turned off key genes responsible for making cancer stem cells resistant to conventional drugs.
UCLA researchers propose an unconventional approach to controlling HIV epidemics by implementing PrEP programs in areas with low treatment success and high drug resistance rates. This strategy aims to decrease the number of infections, resulting in a greater decrease in drug resistance.
New research reveals that Candida tropicalis can mate sexually, contrary to its long-held reputation as an asexual organism. This discovery may allow the species to evolve faster and develop increased virulence or drug resistance.
Researchers at Karolinska Institutet found that blood proteins EPO and PDGF-BB contribute to cancer tumour development and proliferation. The study suggests a potential therapeutic approach by targeting both proteins.
Researchers have identified new ways to target and kill the malaria parasite in human bloodstreams, which could lead to the development of new anti-malarial drugs. The discovery provides a promising avenue for combating the disease, but also highlights the need for continued efforts to address growing resistance to current treatments.
A study found contrasting patterns of malaria drug resistance in human blood and mosquito midgut samples, with pyrimethamine-resistant parasites dominating human blood and cycloguanil-resistant mutants prevalent in mosquitoes.
UCSF researchers have discovered the molecular basis for tamoxifen resistance and found a potential way to defeat it. They showed that cells can develop resistance through epigenetic modification, specifically by elevating expression of the 'survival' gene AKT.
Pediatric oncologists and biochemists advance treatment options for neuroblastoma by studying tumor biology at the molecular level. The study found that certain ALK mutations make cancer cells more resistant to crizotinib, but increasing dosage may overcome this resistance.
Scientists discovered a deadly parasite with duplicated, tripled, and quadrupled chromosomes, defying nature's rule. This bizarre occurrence could be an adaptation to survive harsh environmental stresses, such as drug pressure.
Researchers found that a mushroom compound, verticillin A, improves the efficacy of cancer drugs like TRAIL and etoposide by sensitizing cancer cells to cell death. The compound works by upregulating a gene called BN1P3, which promotes cell death and makes cancer cells more responsive to TRAIL.
A new study reveals that antivirulence drugs can suppress resistance in pathogens by targeting social interactions and cooperation. Laboratory simulations showed that resistant strains will not overtake sensitive strains when therapies target cell-to-cell communication, allowing antivirulence therapies to work even when resistance arises.
Over the past decade, antiretroviral therapy has effectively managed HIV in adults with virological failure to all three original drug classes. Since 2000, nearly one in five patients achieved undetectable viral loads after treatment failure, increasing to nearly three in five by 2009.
Researchers mapped the global spread of drug-resistant influenza, revealing that genetic mutations and human migration through air travel can lead to rapid transmission. The study suggests that a combination of factors, including overuse of antiviral drugs and human movement, contribute to the emergence of resistant strains.
Researchers at Moffitt Cancer Center have developed a monitoring technology that can provide a better understanding of drug resistance in multiple myeloma and assist in individualized patient treatments. The technique uses Liquid Chromatography Multiple Reaction Monitoring (LC-MRM) to quantify biomarkers of human disease.
Researchers have identified the key features in yeast cells that allow them to colonize human tissue, paving the way for new treatments. A new class of medicines and vaccines is being developed to combat drug-resistant fungal infections.
A new study published in Archives of Physical Medicine and Rehabilitation found that higher volume of resistance training combined with aerobic exercise did not yield additional benefits for patients undergoing cardiac rehabilitation. However, the combination of RT and AT resulted in substantial physical fitness benefits and reductions...
A Miriam Hospital study found that male and female smokers who completed a 12-week resistance training regimen were twice as likely to successfully quit compared to those without weight lifting. The study also showed long-lasting effects, with 15% of participants maintaining their quit attempt three months after the study.
Research warns that using powerful antibiotics to treat diseases like MRSA and malaria can accelerate the emergence of resistant strains. The study suggests strategies for slowing resistance spread and preventing mutations.
Researchers at UCLA's Jonsson Comprehensive Cancer Center developed combination treatments to combat BRAF gene mutations in melanoma. The study identified optimal combinations of molecules to block key pathways, showing promise for extending treatment effectiveness and improving patient outcomes.
Researchers found that combining tamoxifen with dasatinib reverses chemo-resistance caused by cancer-associated fibroblasts. The combination normalized glucose intake and reduced mitochondrial oxidative stress, leading to nearly 80% cell death.
Researchers identified a new gonorrhea strain, H041, with extreme resistance to cephalosporin-class antibiotics. This discovery poses a significant threat to public health as the last remaining effective treatments are no longer effective against the bacterium.
A new mathematical model predicts the location of mutations that lead to HIV-drug resistance, providing a potential solution to improve anti-HIV drug design. The study suggests that understanding these physical properties and interactions can help develop better strategies for combating the virus.
A new study found that ivermectin dramatically reduces malaria transmission among people living in Senegalese villages. Ivermectin was administered as part of a campaign to fight onchocerciasis and appeared to kill malaria-carrying mosquitoes, resulting in a 79% decline in mosquitoes carrying Plasmodium falciparum.
A new Cochrane Systematic Review finds that Rapid Diagnostic Tests (RDTs) are highly accurate in detecting malaria parasites, with a success rate of at least 19 out of 20 cases. This development holds promise for improving diagnosis and treatment of malaria in resource-constrained settings.
Researchers have identified specific resistance mutations in the p7 protein that may explain the lack of effectiveness of current p7 inhibitor drugs. The study supports the use of combination therapies inhibiting p7 as a potential component of future HCV-specific treatments, offering new hope for effective therapies.
A new research area seeks to discover ways to manage the evolution of drug-resistant disease organisms and slow their spread. The goal is to develop a science-based model for drug-resistance management that can inform treatment guidelines for various diseases, including malaria, MRSA, AIDS, and cancer.
A phase II clinical trial found PCI-32765 to be highly active in treating chronic lymphocytic leukemia (CLL), achieving complete remission in one patient and partial remissions in 62% of previously untreated patients, with tolerable side effects.
Scientists have discovered a protein involved in drug resistance in breast cancer, which could be targeted for new treatments. Blocking the production of this protein in human cells made them more responsive to anti-oestrogen drugs.
A U-M study found that a curcumin-based compound, FLLL32, can improve the effectiveness of head and neck cancer treatment by sensitizing resistant cells to chemotherapy. The compound decreases activation levels of STAT3, making tumor cells more susceptible to cisplatin.
Researchers identified Abcc10 as a key player in resisting certain anticancer drugs, including taxanes. Blunting its activity may help counteract resistance and make these drugs more effective, providing hope for improved treatment options.
Ionita Ghiran's novel device uses magnetic levitation and cell phone technology to diagnose malaria outside the laboratory setting. The device is inexpensive, portable, and requires only a drop of finger-prick blood, providing a solution to the lack of suitable methods for malaria diagnosis.
A recent study found that nearly 40% of virological breakthroughs in patients receiving nucleoside analogs for chronic hepatitis B were not related to antiviral drug resistance. Non-adherence to medication was identified as a common cause of reemergence.
A novel potential drug-target for colorectal cancer treatment has been identified in a brain-derived protein. Brain-derived neurotrophic factor (BDNF) is present in greater amounts in colorectal tumors and may be involved in CRC progression and resistance to drugs.